PDCD1 and hepatocellular carcinoma: Nonetheless, the overall response rate of HCC to PD‐1/PD‐L1 antibodies remains unsatisfactory (pembrolizumanb, 18.3%; nivolumab, 15.0%; camrelizumab, 14.7%), and few patients achieve complete remission due to primary or acquired ICB resistance.4, 5, 6